HS2 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Technology RevenueWith about 90% of Henry Schein One revenue recurring and 13,000 subscribers, the technology platform can provide repeatable revenue beyond product distribution. Subscriber growth and recurring customer relationships can improve retention and diversify the business over the next several quarters.
Scale And Market PositionA broad global distribution network, more than one million customers, and over 300 solutions support purchasing convenience and operating scale. This footprint can reinforce customer relationships, expand cross-selling opportunities, and sustain Henry Schein’s position in professional healthcare distribution.
Raised Outlook And Improvement ProgramHigher sales and EPS guidance, together with a targeted $200 million-plus operating-income improvement program, indicates management expects continued growth and identifiable efficiency gains. The planned benefits can support earnings durability if execution remains consistent through 2026.
Bears Say
Higher LeverageDebt-to-equity has increased substantially over several years, reaching about 1.15 in the trailing twelve months. Although equity remains solid, the higher debt load reduces financial flexibility and can constrain acquisitions, repurchases, or other investments if operating conditions weaken.
Sustained Margin CompressionNet margin has compressed materially despite continued revenue growth, while recent gross and EBIT margins remain broadly stable rather than expanding. Lower profit conversion leaves less earnings buffer and makes sustained improvement dependent on efficiency initiatives and better operating leverage.
Leadership Transition Execution RiskThe incoming CFO transition and broader leadership changes introduce execution risk during a period that also includes transformation and value-creation initiatives. Maintaining financial discipline, reporting continuity, and strategic momentum will be important as responsibilities shift across the organization.
Henry Schein News
HS2 FAQ
What was Henry Schein’s price range in the past 12 months?
Currently, no data Available
What is Henry Schein’s market cap?
Henry Schein’s market cap is CHF7.87B.
When is Henry Schein’s upcoming earnings report date?
Henry Schein’s upcoming earnings report date is Nov 03, 2026 which is in 25 days.
How were Henry Schein’s earnings last quarter?
Henry Schein released its earnings results on Aug 04, 2026. The company reported CHF1.057 earnings per share for the quarter, beating the consensus estimate of CHF1.032 by CHF0.025.
Is Henry Schein overvalued?
According to Wall Street analysts Henry Schein’s price is currently Undervalued.
Does Henry Schein pay dividends?
Henry Schein does not currently pay dividends.
What is Henry Schein’s EPS estimate?
Henry Schein’s EPS estimate is 1.13.
How many shares outstanding does Henry Schein have?
Currently, no data Available
What happened to Henry Schein’s price movement after its last earnings report?
Henry Schein reported an EPS of CHF1.057 in its last earnings report, beating expectations of CHF1.032. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Henry Schein?
Currently, no hedge funds are holding shares in CH:HS2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Henry Schein Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF84.24 (― Upside)
CHF84.24 (― Upside)
Blogger Sentiment
Bullish
CH:HS2 Sentiment 83%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.94%
12-Months-Change
Fundamentals
Return on Equity
12.37%
Trailing 12-Months
Asset Growth
4.36%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Henry Schein
Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.
HS2 Company Deck
HS2 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial update: solid top-line growth (6.7%), expanding margins, double-digit non-GAAP EPS growth (15.5%), strong adjusted EBITDA growth (12.7%), and raised full-year guidance. Management reinforced a clear value-creation program with specific savings targets ($125M run-rate by end-2026; $200M+ over time) and early implementation steps producing measurable benefits. Technology and recurring-revenue businesses (Dentrix Ascend / Henry Schein One) showed notable strength and strategic potential. Near-term headwinds include a small decline in U.S. dental equipment, lower point-of-care diagnostic demand, meaningful Q2 restructuring charges ($29M), and reduced remeasurement gains versus prior year, which constrain GAAP clarity and EPS flow-through. Overall, the positive metrics, guidance raise, and credible execution plan outweigh the localized challenges and one-time costs.View all CH:HS2 earnings summariesHS2 Revenue Breakdown
84.48% Global Distribution and Value-Added Services
11.71% Global Specialty Products
5.12% Global Technology
-1.31% Eliminations
